What's behind the FDA’s controversial strategy for evaluating new COVID boosters

Paul Offit of the Perelman School of Medicine says that the FDA needs solid data to ensure that the new BA.4/5 boosters have a dramatically greater neutralizing antibody response.

・ From NPR